![Malte Peters](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Malte Peters
Chief Executive Officer at
TANGO THERAPEUTICS, INC.
Net worth: 280 688 $ as of 30/09/2026
Profile
Malte Peters is currently Chief Executive Officer & Director at HOOKIPA Pharma, Inc. since 2024.
Since 2018, holds the positions of President, Chief Executive Officer & Director at Tango Therapeutics, Inc., Director at Tango Therapeutics Sub, Inc., Director-Cancer Research at Merck KGAA Unsponsored ADR Facility, and Research Scientist at Amgen NV.
Formerly Chief Executive Officer & Director at Hookipa Biotech AG in 2024.
Served as Director-Cancer Research at Merck KGaA from 2003 to 2004 and Medical Director at Micromet AG during the same period.
From 2004 to 2015, was Head-Clinical, Site Head-Basel & East Hanover at Novartis AG.
From 2015 to 2017, was Global Head-Clinical Development at Sandoz International GmbH.
From 2020 to 2022, was Chief Research & Development Officer at MorphoSys AG.
Education includes a doctorate from Freie Universität Berlin.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/04/2026 | 11,250 ( 0.01% ) | 280 688 $ | 30/09/2026 |
Malte Peters active positions
| Companies | Position | Start |
|---|---|---|
| TANGO THERAPEUTICS, INC. | Chief Executive Officer | 08/01/2026 |
Tango Therapeutics Sub, Inc.
 Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Develops transformational new drugs for cancer patients | Director/Board Member | 10/10/2018 |
Amgen NV
 Amgen NV Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for patients with serious illness | Corporate Officer/Principal | - |
Merck KGAA Unsponsored ADR Facility | Corporate Officer/Principal | - |
Former positions of Malte Peters
| Companies | Position | End |
|---|---|---|
| HOOA PHARPAR | Chief Executive Officer | 01/07/2026 |
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Develops new generation prophylactic and therapeutic vaccines | Chief Executive Officer | 18/11/2024 |
| MORPHOSYS AG | Chief Tech/Sci/R&D Officer | 01/10/2022 |
Sandoz International GmbH
 Sandoz International GmbH Pharmaceuticals: GenericHealth Technology Develops and manufactures generic pharmaceuticals | Corporate Officer/Principal | 01/02/2017 |
| NOVARTIS AG | Chief Tech/Sci/R&D Officer | 01/05/2015 |
Education of Malte Peters
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
85
1st degree connections
12
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 12 |
|---|---|
Merck KGaA
 Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products | Health Technology |
Merck KGAA Unsponsored ADR Facility | |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
MorphoSys AG
 MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
Micromet AG
 Micromet AG Pharmaceuticals: MajorHealth Technology Manufactures and markets drugs | Health Technology |
Sandoz International GmbH
Sandoz International GmbH Pharmaceuticals: GenericHealth Technology Develops and manufactures generic pharmaceuticals | Health Technology |
Freie Universität Berlin
 Freie Universität Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Amgen NV
Amgen NV Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for patients with serious illness | Health Technology |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Develops new generation prophylactic and therapeutic vaccines | Health Technology |
Tango Therapeutics Sub, Inc.
Tango Therapeutics Sub, Inc. BiotechnologyHealth Technology Develops transformational new drugs for cancer patients | Health Technology |
HOOKIPA Pharma, Inc.
 HOOKIPA Pharma, Inc. BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company which develops pharmaceutical products for immunotherapeutic targeting infectious diseases and cancers | Health Technology |
Tango Therapeutics, Inc.
 Tango Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company that engages in discovering and delivering precision cancer medicines | Health Technology |
- Stock Market
- Insiders
- Malte Peters
